Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy ZEN-3694
Indication/Tumor Type prostate cancer
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown prostate cancer not applicable ZEN-3694 Preclinical - Pdx Actionable In a preclinical study, ZEN-3694 treatment inhibited tumor progression in an AR-positive cell line xenograft model and an AR V7_splice-positive cell line xenograft model of prostate cancer, and inhibited tumor progression in an Xtandi (enzalutamide)-resistant patient-derived xenograft (PDX) model (Cancer Res 2016;76(14 Suppl):Abstract nr LB-207). detail...
PubMed Id Reference Title Details
Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC) Full reference...